EU agency supports new use of Merck's Gardasil
LONDON, June 2 (Reuters) - The European Medicines Agency has recommended that Merck & Co Inc's (MRK.N) cervical cancer vaccine Gardasil should also be approved for the prevention of high-grade vaginal dysplastic lesions.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
Gardasil is marketed in Europe via a 50:50 joint venture company with Sanofi-Aventis SA (SASY.PA). It competes with GlaxoSmithKline Plc's (GSK.L) rival product Cervarix. (Reporting by Ben Hirschler)
© Thomson Reuters 2009 All rights reserved
Citadel enters the fray
Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies. Full Article | Full Coverage
